As a part of its universal influenza vaccine program, Inovio has designed and manufactured consensus DNA vaccines for H1N1 influenza strains. These consensus vaccines, delivered using Inovio's proprietary electroporation technology, have the potential to provide protection against a broad scope of existing as well as currently unknown, unmatched influenza strains that could emerge - one of the perpetual challenges in trying to protect against influenza, the company said.
The purpose of this collaboration is to test these vaccine candidates against pandemic and seasonal influenza strains in animal models and will include testing against a recently identified swine H1N1 strain.
Inovio's influenza vaccine constructs were designed using the company's novel SynCon technology, which facilitates the design of DNA-based vaccines capable of protecting against unmatched sub-types and strains of pathogens.
Joseph Kim, Inovio's CEO, said: "The current swine flu outbreak highlights the fact that the world cannot rely solely on the 'catch-up' strategy of influenza vaccine design. We need vaccines that provide at least some broad protective capability against evolving seasonal influenza strains and those with pandemic potential.
"We have already achieved significant validating data in large animal models regarding the ability of Inovio's consensus vaccines to protect against unmatched strains of different influenza sub-types and look forward to the data resulting from this collaboration of vaccine experts."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index